| Display title | Chemistry:Faldaprevir |
| Default sort key | Faldaprevir |
| Page length (in bytes) | 4,090 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 517782 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Len Stevenson |
| Date of page creation | 05:08, 6 February 2024 |
| Latest editor | imported>Len Stevenson |
| Date of latest edit | 05:08, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become... |
